One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: The APOLLO study

Yuji Oshima, Kenichi Kimoto, Noriko Yoshida, Kimihiko Fujisawa, Shozo Sonoda, Toshiaki Kubota, Toshinori Murata, Taiji Sakamoto, Shigeo Yoshida, Koh Hei Sonoda, Tatsuro Ishibashi

研究成果: ジャーナルへの寄稿記事

11 引用 (Scopus)

抄録

Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naïve PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6% of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001). Mean central foveal thickness decreased from 356 to 239 μm (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5% after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients.

元の言語英語
ページ(範囲)163-171
ページ数9
ジャーナルOphthalmologica
238
発行部数3
DOI
出版物ステータス出版済み - 9 1 2017

Fingerprint

Intravitreal Injections
Visual Acuity
Multicenter Studies
Therapeutics
aflibercept
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems

これを引用

One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients : The APOLLO study. / Oshima, Yuji; Kimoto, Kenichi; Yoshida, Noriko; Fujisawa, Kimihiko; Sonoda, Shozo; Kubota, Toshiaki; Murata, Toshinori; Sakamoto, Taiji; Yoshida, Shigeo; Sonoda, Koh Hei; Ishibashi, Tatsuro.

:: Ophthalmologica, 巻 238, 番号 3, 01.09.2017, p. 163-171.

研究成果: ジャーナルへの寄稿記事

Oshima, Y, Kimoto, K, Yoshida, N, Fujisawa, K, Sonoda, S, Kubota, T, Murata, T, Sakamoto, T, Yoshida, S, Sonoda, KH & Ishibashi, T 2017, 'One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: The APOLLO study', Ophthalmologica, 巻. 238, 番号 3, pp. 163-171. https://doi.org/10.1159/000477448
Oshima, Yuji ; Kimoto, Kenichi ; Yoshida, Noriko ; Fujisawa, Kimihiko ; Sonoda, Shozo ; Kubota, Toshiaki ; Murata, Toshinori ; Sakamoto, Taiji ; Yoshida, Shigeo ; Sonoda, Koh Hei ; Ishibashi, Tatsuro. / One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients : The APOLLO study. :: Ophthalmologica. 2017 ; 巻 238, 番号 3. pp. 163-171.
@article{2959dcb4e86f48a69787e6c0cfd95b02,
title = "One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: The APOLLO study",
abstract = "Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-na{\"i}ve PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6{\%} of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001). Mean central foveal thickness decreased from 356 to 239 μm (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5{\%} after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients.",
author = "Yuji Oshima and Kenichi Kimoto and Noriko Yoshida and Kimihiko Fujisawa and Shozo Sonoda and Toshiaki Kubota and Toshinori Murata and Taiji Sakamoto and Shigeo Yoshida and Sonoda, {Koh Hei} and Tatsuro Ishibashi",
year = "2017",
month = "9",
day = "1",
doi = "10.1159/000477448",
language = "English",
volume = "238",
pages = "163--171",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients

T2 - The APOLLO study

AU - Oshima, Yuji

AU - Kimoto, Kenichi

AU - Yoshida, Noriko

AU - Fujisawa, Kimihiko

AU - Sonoda, Shozo

AU - Kubota, Toshiaki

AU - Murata, Toshinori

AU - Sakamoto, Taiji

AU - Yoshida, Shigeo

AU - Sonoda, Koh Hei

AU - Ishibashi, Tatsuro

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naïve PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6% of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001). Mean central foveal thickness decreased from 356 to 239 μm (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5% after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients.

AB - Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naïve PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6% of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001). Mean central foveal thickness decreased from 356 to 239 μm (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5% after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients.

UR - http://www.scopus.com/inward/record.url?scp=85023756812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023756812&partnerID=8YFLogxK

U2 - 10.1159/000477448

DO - 10.1159/000477448

M3 - Article

C2 - 28697497

AN - SCOPUS:85023756812

VL - 238

SP - 163

EP - 171

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 3

ER -